Denys, Hannelore <br/><br/>
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.  [electronic resource] 

 -  Breast cancer research and treatment  May 2020 
 - 97-105 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-020-05604-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Belgium<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Carcinoma, Lobular--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Subcutaneous<br/>Israel<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Prognosis<br/>Prospective Studies<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Trastuzumab--administration & dosage<br/>Young Adult